{"nctId":"NCT01694966","briefTitle":"The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy","startDateStruct":{"date":"2013-09"},"conditions":["Colorectal Cancer"],"count":1249,"armGroups":[{"label":"Methylene Blue MMX® 200mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methylene Blue MMX®"]},{"label":"Methylene Blue MMX® 100mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methylene Blue MMX®","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Methylene Blue MMX®","otherNames":["Investigational Product: Methylene Blue MMX® modified release tablets","Active Ingredient: Methylene Blue"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females, aged between 50 and 75.\n* Outpatients scheduled for screening or surveillance colonoscopy for polyps or colorectal cancer )\n* Able to comprehend the full nature and purpose of the study, including possible risks and side effects.\n* Able to co-operate with the investigator and to comply with the requirements of the entire study.\n* Signed written informed consent prior to inclusion in the study.\n\nExclusion Criteria:\n\n* Patients at high risk of colorectal cancer e.g. ulcerative colitis\n* Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.\n* Previous medical history of, or suspected hypersensitivity to, the PEG based bowel cleansing preparation and/or bowel cleansing formulations' ingredients.\n* Previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, ulcerative colitis or Crohn's disease.","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.","description":"Adenoma Detection Rate","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"51.5","spread":null},{"groupId":"OG002","value":"47.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":485},"commonTop":["chromaturia","faeces discoloured"]}}}